The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Orexigen Therapeutics Inc

Nasdaq: OREX
Last

(U.S.) $7.36

Today's change-0.08 -1.08%
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.
 

Orexigen Therapeutics Inc

Nasdaq: OREX
Last

(U.S.) $7.36

Today's change-0.08 -1.08%
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.

Orexigen Therapeutics Inc down (U.S.)$0.08

Orexigen Therapeutics Inc closed lower Friday, dropping (U.S.)$0.08 or 1.08% to (U.S.)$7.36. Shares have lost 2.39% over the last five days, but have gained 21.45% over the last year to date. This security has outperformed the S&P 500 by 20.37% during the last year.

Key company metrics

  • Open(U.S.) $7.41
  • Previous close(U.S.) $7.44
  • High(U.S.) $7.58
  • Low(U.S.) $7.28
  • Bid / Ask-- / --
  • YTD % change+21.45%
  • Volume2,337,635
  • Average volume (10-day)2,737,511
  • Average volume (1-month)3,762,123
  • Average volume (3-month)5,501,441
  • 52-week range(U.S.) $3.11 to (U.S.) $9.37
  • Beta2.43
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.34
Updated April 24 4:00 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue233111
Total other revenue--------
Total revenue233111
Gross profit--------
Total cost of revenue--------
Total operating expense21182424
Selling / general / administrative8777
Research & development13111717
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income213-23-23
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax111-25-25
Income after tax111-25-25
Income tax, total----00
Net income111-25-25
Total adjustments to net income--------
Net income before extra. items111-25-25
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items111-25-25
Inc. avail. to common incl. extra. items111-25-25
Diluted net income111-25-25
Dilution adjustment----00
Diluted weighted average shares123130118109
Diluted EPS excluding extraordinary itemsvalue per share0.000.09-0.21-0.23
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.000.09-0.21-0.23